Global disease burden due to antibiotic resistance -state of the evidence, J Glob Health, vol.6, p.10306, 2016. ,
Tackling the threat of antimicrobial resistance: from policy to sustainable action, Philos Trans R Soc Lond B Biol Sci, vol.370, 2015. ,
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE, J Infect Dis, vol.197, pp.1079-81, 2008. ,
Analysis of the clinical antibacterial and antituberculosis pipeline, Lancet Infect Dis, 2018. ,
Alternatives to overcoming bacterial resistances: state-of-the-art ,
, Microbiol Res, vol.191, pp.51-80, 2016.
Global biogeographic sampling of bacterial secondary metabolism, Elife, vol.4, p.5048, 2015. ,
A new antibiotic kills pathogens without detectable resistance, Nature, vol.517, pp.455-464, 2015. ,
Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens, Nat Microbiol, vol.3, pp.415-437, 2018. ,
The quest for novel antimicrobial compounds: emerging trends in research, development, and technologies, Antibiotics (Basel), vol.8, p.8, 2019. ,
Recent application of metagenomic approaches toward the discovery of antimicrobials and other bioactive small molecules, Curr Opin Microbiol, vol.13, pp.603-612, 2010. ,
Antibiotic dialogues: induction of silent biosynthetic gene clusters by exogenous small molecules, FEMS Microbiol Rev, vol.41, pp.19-33, 2017. ,
Design and discovery of new antibacterial agents: advances, perspectives, challenges, Curr Med Chem, vol.25, pp.4972-5006, 2018. ,
Beta-lactams and beta-lactamase inhibitors: an overview, Cold Spring Harb Perspect Med, vol.6, 2016. ,
Antibiotic hybrids: the next generation of agents and adjuvants against Gram-negative pathogens?, Clin Microbiol Rev, p.31, 2018. ,
vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics, Proc Natl Acad Sci, vol.114, pp.5052-61, 2017. ,
Porous silicon nanoparticle delivery of tandem peptide anti-infectives for the treatment of Pseudomonas aeruginosa lung infections, Adv Mater, vol.29, 2017. ,
Nanoparticles: alternatives against drugresistant pathogenic microbes, Molecules, vol.21, 2016. ,
Promising recent strategies with potential clinical translational value to combat antibacterial resistant surge, Medicines (Basel), vol.6, p.21, 2019. ,
Phages, fitness, virulence, and synergy: a novel approach for the therapy of infections caused by Pseudomonas aeruginosa, J Infect Dis, vol.215, pp.668-70, 2017. ,
Phage therapy: past, present and future, Front Microbiol, vol.8, p.981, 2017. ,
Phage therapy in the postantibiotic era, Clin Microbiol Rev, vol.32, pp.66-84, 2019. ,
Development of phage lysins as novel therapeutics: a historical perspective, Viruses, vol.10, 2018. ,
Bacteriophage endolysins as novel antimicrobials, Future Microbiol, vol.7, pp.1147-71, 2012. ,
Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies, Clin Microbiol Rev, p.31, 2018. ,
Vaccination to reduce antimicrobial resistance, Lancet Glob Health, vol.6, p.252, 2018. ,
How Can vaccines contribute to solving the antimicrobial resistance problem?, MBio, vol.7, 2016. ,
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland, N Engl J Med, vol.350, pp.896-903, 2004. ,
Antibacterial monoclonal antibodies: the next generation?, Curr Opin Microbiol, vol.27, pp.78-85, 2015. ,
Inhibition and reversal of microbial attachment by an antibody with parasteric activity against the FimH adhesin of uropathogenic E. coli, PLoS Pathog, vol.11, p.1004857, 2015. ,
Bezlotoxumab for prevention of recurrent Clostridium difficile infection, N Engl J Med, vol.376, pp.305-322, 2017. ,
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus, Nature, vol.527, pp.323-331, 2015. ,
DOI : 10.1038/nature16057
Modulating immunity as a therapy for bacterial infections, Nat Rev Microbiol, vol.10, pp.243-54, 2012. ,
DOI : 10.1038/nrmicro2745
Pharmacological targeting of the host-pathogen interaction: alternatives to classical antibiotics to combat drug-resistant superbugs, Trends Pharmacol Sci, vol.38, pp.473-88, 2017. ,
Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies, Nat Biotechnol, vol.24, pp.1551-1558, 2006. ,
DOI : 10.1038/nbt1267
Antimicrobial peptides for therapeutic applications: a review, Molecules, vol.17, pp.12276-86, 2012. ,
An anti-infective peptide that selectively modulates the innate immune response, Nat Biotechnol, vol.25, pp.465-72, 2007. ,
Predictive modelling of a novel anti-adhesion therapy to combat bacterial colonisation of burn wounds, PLoS Comput Biol, vol.14, p.1006071, 2018. ,
Novel strategies to combat bacterial virulence, Curr Opin Crit Care, vol.14, pp.593-602, 2008. ,
The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG, Expert Rev Vaccines, vol.15, pp.1041-53, 2016. ,
Learning from bacterial competition in the host to develop antimicrobials, Nat Med, vol.24, pp.1097-103, 2018. ,
Related actions of probiotics and antibiotics on gut microbiota and weight modification, Lancet Infect Dis, vol.13, pp.889-99, 2013. ,
Duodenal infusion of donor feces for recurrent Clostridium difficile, N Engl J Med, vol.368, pp.407-422, 2013. ,
Efflux pump inhibitors: a novel approach to combat efflux-mediated drug resistance in bacteria, Curr Drug Targets, vol.17, pp.702-721, 2016. ,
An update on ?-lactamase inhibitor discovery and development, Drug Resist Updat, vol.36, pp.13-29, 2018. ,
Novel beta-lactamase inhibitors: unlocking their potential in therapy, Drugs, vol.77, pp.615-643, 2017. ,
Revitalizing the drug pipeline: AntibioticDB, an open access database to aid antibacterial research and development, J Antimicrob Chemother, vol.73, pp.2284-97, 2018. ,
Conjugation Inhibitors and their potential use to prevent dissemination of antibiotic resistance genes in bacteria, Front Microbiol, vol.8, p.2329, 2017. ,
The oral ?-lactamase SYN-004 (ribaxamase) degrades ceftriaxone excreted into the intestine in phase 2a clinical studies, Antimicrob Agents Chemother, vol.61, pp.2197-2213, 2017. ,
Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: a proof of concept study in healthy subjects, J Clin Pharmacol, vol.55, pp.10-16, 2015. ,
Antimicrobial peptides, J Am Acad Dermatol, vol.52, pp.381-90, 2005. ,
Bacteriocins and their position in the next wave of conventional antibiotics, Int J Antimicrob Agents, vol.46, pp.494-501, 2015. ,
Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens, PLoS Pathog, vol.14, p.1007084, 2018. ,
Predatory bacteria: a potential ally against multidrug-resistant Gramnegative pathogens, PLoS One, vol.8, p.63397, 2013. ,
Cyanide Production by Chromobacterium piscinae shields it from Bdellovibrio bacteriovorus HD100 predation, MBio, vol.8, 2017. ,
Regulatory RNAs in bacteria, Cell, vol.136, pp.615-643, 2009. ,
A small RNA controls a protein regulator involved in antibiotic resistance in Staphylococcus aureus, Nucleic Acids Res, vol.42, pp.4892-905, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-00951043
Non-coding RNAs as antibiotic targets, Biochem Pharmacol, vol.133, pp.29-42, 2017. ,
CRISPR-based antibacterials: transforming bacterial defense into offense, Trends Biotechnol, vol.36, pp.127-157, 2018. ,
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials, Nat Biotechnol, vol.32, pp.1146-50, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01103559
Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals, Antimicrob Agents Chemother, vol.59, pp.3695-3704, 2015. ,
Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps, J Antibiot (Tokyo), vol.70, pp.1087-96, 2017. ,
, Update of antibacterial agents in clinical development, WHO, 2018.
The infectious diseases society of America's 10 x '20 inititative (ten new systemic antibacterial agents FDA-approved by 2020): is 20 x '20 a possibility?, Clin Infect Dis, 2019. ,